In the mechanical thrombectomy market, Possis currently serves only 14 percent of the current realizable U.S. market. Combine that with an aging population, who will increasingly experience coronary and vascular problems, and emerging therapy needs such as DVT, PE and ischemic stroke, and you have a clear opportunity for future growth.